Levetiracetam in nonconvulsive status epilepticus in a child with Angelman syndrome.
Children with Angelman syndrome have an increased risk of developing a nonconvulsive status epilepticus. Although the urgency to treat nonconvulsive status epilepticus depends on the underlying illness, most clinicians and authors agree that treatment should be focused to rapidly terminate this condition. Until now, the use of levetiracetam to treat nonconvulsive status epilepticus in children is based only on some case reports. Our case further supports this treatment regime for a subgroup of children with a special risk of nonconvulsive status epilepticus and developmental delay.
Weber
Peter
P
Division of Neuropediatrics and Developmental Medicine, University Children's Hospital Basel, Basel, Switzerland. Peter.Weber@ukbb.ch
D017204:Angelman Syndrome / Q000150:complications* / Q000503:physiopathology; D000927:Anticonvulsants / Q000627:therapeutic use*; D001921:Brain / Q000503:physiopathology; D002648:Child; D004569:Electroencephalography; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013226:Status Epilepticus / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam